Google Cloud Launches AI Tools To Speed Up Drug Development Process

As we speak, the way drugs are developed is being rewritten. The discovery and approval of new drugs is a long process requiring years of development time and dismal success rates, but artificial intelligence (AI) has the potential to greatly improve this process.

On May 15th, Google Cloud released two new AI-powered tools, the Target and Lead Identification Suite and the Multiomics Suite, designed to help biotech and pharmaceutical companies accelerate drug discovery and advance medicine. bottom.

Today, new drug development takes 12-15 years, from idea to final product deployment, and can cost upwards of $1 billion. study Published in the March 2021 issue British Journal of Pharmacology. Additionally, identifying the biological target required for an effective drug can take up to 12 months according to US patents. NIH, National Center for Biotechnology Information.

These tools have the potential to replace traditional tools. X-ray crystallography and nuclear magnetic resonance (NMR), two major processes for determining the 3D structure of proteins, are necessary biological targets for the first steps in drug development, but have high failure rates. .

announced in Bio IT World Congress An event will be held May 16-18 at the Hynes Convention Center in Boston, Massachusetts to “showcase the technologies and analytical approaches that solve problems, accelerate science, and drive the future of precision medicine.” The event featured speakers from Pfizer, Janssen Pharmaceuticals and Harvard Medical School.

CNBC report The Target and Lead Identification Suite is designed to help biotech and pharmaceutical companies predict and understand the structures of proteins, which are a fundamental part of drug development. This allows scientists to share and manage protein molecular data using Google Cloud capabilities. analytics hub to exchange data securely.

Researchers then use the data to predict protein structures. alpha fold 2, A machine learning model developed by a subsidiary of Google. AlphaFold2 works on Google Vertex AIa platform that allows researchers to build and deploy machine learning models faster.

AlphaFold2 can predict 3D structures of proteins with high accuracy within “minutes”.

Meanwhile, the Multiomics Suite helps researchers capture, store, analyze, and share large amounts of genomic data. This suite helps researchers embark on genomic data analysis.

CNBC reported that biotech firm Colossal Biosciences has set a goal of using DNA and genetic engineering to “reverse extinctions.”

Researchers can sequence DNA much faster than it takes to decode and analyze it. But technology has provided genomic data in areas such as genetic variations associated with disease.

The Investigational New Drug (IND) quest in biotech often overlaps with the cannabis industry, and Google’s new tool could transform the business of certain companies.

Shweta Maniar is the Global Director of Life Sciences Strategy and Solutions at Google Cloud. “We are helping organizations get medicines to the right people faster,” said Mania. Said CNBC. “I am personally very excited. This is something that myself and the team have been working on for several years.”

The first critical step in drug development is identifying a biological target to focus on and design therapeutics. Biological targets are the most common. protein, are the building blocks of disease and other life forms. And to find a target, researchers need to identify the structure of the protein that determines its function in disease.

“Once we understand the structure and role of proteins, we can start developing drugs based on that,” says Mania.

As technology continues to advance, the AI ​​market is projected to reach trillions of dollars. Google announced his ChatGPT on OpenAI in late 2021. Generative Chatbot Bard in February.